Navigation Links
Surviving ovarian cancer: Rutgers scientists attack drug resistant cancer cells
Date:12/9/2013

Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer in the United States.

Tamara Minko, professor in the Ernest Mario School of Pharmacy and Lorna Rodriguez, professor of obstetrics and gynecology at Rutgers Cancer Institute of New Jersey, say because there is not a good screening method for ovarian cancer, most women with the disease are not diagnosed until after it has metastasized to other organs and surgery and chemotherapy are not as effective.

"Once the ovarian cancer becomes drug resistant we cannot cure it," says Rodriguez an oncologist who provides treatment to ovarian cancer patients. "Circumventing the development of drug resistance is a reasonable approach and very much needed."

The main reason for advanced-stage ovarian cancer, they say, is an out of control protein CD44, which enables cancerous tumors to proliferate and become resistant to conventional drug treatments. The result: a five-year survival rate for patients with advanced-stage ovarian cancer that is only 30 percent.

In a new study published in Clinical Cancer Research, Minko and Rodriguez provide results of animal research in which the cancer is attacked at the genetic level by using small, inhibiting RNA molecules that directly target and decrease the excess CD44 protein in cancer cells while simultaneously treating patients with the anti-cancer drug paclitaxel. This allows cells within the cancerous tumors to be successfully treated even at an advanced stage.

"We expect that the proposed treatment will be especially effective in advanced stages of ovarian cancers, where there are many cancer stem cells in the tumors that resist conventional drug treatment," says Minko.

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory mice. They then used a combination of chemotherapy and gene therapy to target the cancer cells directly in order to inhibit growth and prevent metastasis while sparing normal healthy cells. The treatment killed cancerous cells in the mice, shrunk their tumors and left them with fewer side effects.

Since the CD44 protein is expressed on the surface of many cancer stem cells, the approach developed by Rutgers scientists may help in the treatment of other types of cancers. The next step for ovarian cancer research would be to develop a drug for human consumption that could be used in clinical trials. This, they say, could lead to new pharmacological cancer treatments and increase the survival rate of the deadly disease.


'/>"/>

Contact: Robin Lally
rlally@ucm.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert

Related medicine news :

1. Former Athlete Credits Sports for Surviving Horrible Car Accident and Lengthy Coma
2. Stage I NSCLC patients who receive radiation therapy are surviving longer
3. Floodmasters 5 Tips to Surviving the Next Hurricane Sandy
4. Too Much Sitting May Lower Odds of Surviving Colon Cancer
5. More Infants Surviving With Serious Heart Defects, Study Finds
6. ParentMagic Inc Releases Enhanced E-Book “Surviving Your Adolescents” Available in iBooks on iOS
7. Study Finds Overweight Young Males Have a Greater Risk of Not Surviving Until Age 55, Making Weight Loss Supplements Like Prescopodene Helpful With Increasing Longevity
8. Surviving a Tornado and Then Facing Homeowner Insurance Battles
9. Parent Magic Inc's "Surviving Your Adolescents" Wins Gold Award in National Parenting Publications Awards 2013
10. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
11. U.S. Panel Rejects Ovarian Cancer Screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care ... Dallas area” Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards ... School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors ...
(Date:12/4/2016)... ... ... Responsible dental care hinges on regular brushing of the teeth. However, just ... necessity inspired an inventor from Las Vegas, Nev., to design the BRUSH PROPER. ... avoid bad techniques of brushing the teeth in order to prevent cavities," he said. ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine ... San Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in ... and beyond the standard of care, demonstrating leadership within the MPN community and/or a ...
(Date:12/2/2016)... Livermore, California (PRWEB) , ... December 02, 2016 ... ... business professionals, proudly announces the launch of its 60-day free trial program for ... round trip shipping make the offer a truly hassle free experience. , FlexiSpot’s ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain ... an injury, patients must find the one that works for them. When an inventor ... a machine that worked and decided to share it with others. , He developed ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... Johnson & Weaver, LLP announces that a class ... Biomet Holdings, Inc. (NYSE: ZBH )  securities during ... (the "Class Period"). Zimmer Biomet provides musculoskeletal healthcare ... products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)... DIEGO , Dec. 3, 2016 Sickle ... by rigid, sickle-shaped red blood cells that get stuck ... severe pain, stroke, organ failure, and complications leading to ... are born with SCD, and most of them lack ... fact, the only established long-term therapy for SCD, a ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: